Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.
Harvard Apparatus Regenerative Technology Total Payout Yield % Explanation
Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.
Harvard Apparatus Regenerative Technology Total Payout Yield % Related Terms
Harvard Apparatus Regenerative Technology Total Payout Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Apparatus Regenerative Technology Total Payout Yield % Chart
Harvard Apparatus Regenerative Technology Annual Data
HRGN vs JVA, BRLS, LIMX: Total Payout Yield % Comparison
For the Packaged Foods subindustry, Harvard Apparatus Regenerative Technology's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Apparatus Regenerative Technology Total Payout Yield % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Harvard Apparatus Regenerative Technology's Total Payout Yield % distribution charts can be found below:
* The bar in red indicates where Harvard Apparatus Regenerative Technology's Total Payout Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Apparatus Regenerative Technology (HRGN) has a Total Payout Yield % of 0.00 as of Jul. 27, 2026. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Harvard Apparatus Regenerative Technology and its competitors.
Is Harvard Apparatus Regenerative Technology's Total Payout Yield % too high?
Harvard Apparatus Regenerative Technology's current Total Payout Yield % is 0.00. Overall, Harvard Apparatus Regenerative Technology has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Apparatus Regenerative Technology's Total Payout Yield % compare to JVA and BRLS?
Harvard Apparatus Regenerative Technology's Total Payout Yield % of 0.00 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Yield % for a Consumer Packaged Goods company?
A good Total Payout Yield % depends on the Consumer Packaged Goods industry context. However, Total Payout Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Yield % mean?
A high Total Payout Yield % can signal that a stock is expensive relative to its fundamentals. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Harvard Apparatus Regenerative Technology and its competitors. Harvard Apparatus Regenerative Technology's current Total Payout Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Apparatus Regenerative Technology stock overvalued right now?
Harvard Apparatus Regenerative Technology (HRGN) has a current Total Payout Yield % of 0.00. The current Total Payout Yield % is 0.00. Harvard Apparatus Regenerative Technology's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Yield % calculated?
Total Payout Yield % is calculated from a company's financial statements. For Harvard Apparatus Regenerative Technology (HRGN), the current Total Payout Yield % is 0.00 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Harvard Apparatus Regenerative Technology Business Description
Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.
14GF Score
Get the complete analysis for HRGN
Total Payout Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HRGN has been successfully added to your 
